Telephone: +82-31-780-1872; Fax: +82-32-780-3449
Translational and Clinical Research
Article first published online: 25 FEB 2013
Copyright © 2012 AlphaMed Press
Volume 31, Issue 3, pages 581–591, March 2013
How to Cite
Min, K., Song, J., Kang, J. Y., Ko, J., Ryu, J. S., Kang, M. S., Jang, S. J., Kim, S. H., Oh, D., Kim, M. K., Kim, S. S. and Kim, M. (2013), Umbilical Cord Blood Therapy Potentiated with Erythropoietin for Children with Cerebral Palsy: A Double-blind, Randomized, Placebo-Controlled Trial. STEM CELLS, 31: 581–591. doi: 10.1002/stem.1304
Author contributions: MY.K.: the principal investigator, conception and design, manuscript writing, provision of patients, data analysis and interpretation, and final approval of manuscript; K.M.: data analysis and interpretation; J.S., JY.K. J.K., and JS.R.: collection and/or assembly of data; MS.K.: provision of study material; SJ.J. and SH.K.: data analysis and interpretation; D.O. and MK.K.: conception and design; SS.K.: data analysis and interpretation.
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS December 24, 2012.
- Issue published online: 25 FEB 2013
- Article first published online: 25 FEB 2013
- Accepted manuscript online: 24 DEC 2012 12:16AM EST
- Manuscript Accepted: 26 NOV 2012
- Manuscript Revised: 30 OCT 2012
- Manuscript Received: 3 SEP 2012
- SungKwang Medical Foundation
Additional Supporting Information may be found in the online version of this article.
|sc-12-0823_sm_supplFigure1.tif||621K||Supporting Information Figure 1. Cyclosporine levels during four weeks of immunosuppression in pUCB group Horizontal bars and shaded area denote median values and the target range of level control (100 to 200 ng/mL), respectively. pUCB group received umbilical cord blood potentiated with rhEPO and rehabilitation|
|sc-12-0823_sm_supplFigure2.tif||486K||Supporting Information Figure 2. Changes in hemoglobin (A) and erythropoietin (B) levels during the study period of six months According to the protocol, hemoglobin level was monitored at 2 weeks, 3 weeks and 4 weeks after recombinant human erythropoietin (rhEPO) administration, and rhEPO was discontinued, when hemoglobin level reached 15g/dL. Bars represent SE. pUCB group received umbilical cord blood potentiated with recombinant human erythropoietin and rehabilitation; EPO group received recombinant human erythropoietin and rehabilitation; Control group received rehabilitation only.|
|sc-12-0823_sm_supplFigure3.pdf||238K||Supporting Information Figure 3. Baseline differences of glucose metabolism activity with 18F-FDG PET in three groups from paired comparisons (p-value < 0.05) Red colored areas indicate higher glucose metabolism in the later group, and blue colored areas represent lower glucose metabolism in the former group. pUCB group received umbilical cord blood potentiated with recombinant human erythropoietin and rehabilitation; EPO group received recombinant human erythropoietin and rehabilitation; Control group received rehabilitation only.|
|sc-12-0823_sm_supplFigure4.tif||572K||Supporting Information Figure 4. Comparing changes in fractional anisotropy (FA) from bilateral posterior lower pons, representing spinothalamic tract, during the period from baseline to 6 months post-treatment between three groups; pUCB group (n = 30), EPO group (n = 31), and Control group (n = 29) Bars represent 95% CI. pUCB group received umbilical cord blood potentiated with recombinant human erythropoietin and rehabilitation; EPO group received recombinant human erythropoietin and rehabilitation; Control group received rehabilitation only. p-values are reported for difference between two groups in FA changes, based on post-hoc analysis after ANOVA test.|
|sc-12-0823_sm_supplTable1.pdf||83K||Supplementary Table 1|
|sc-12-0823_sm_supplTable2.pdf||91K||Supplementary Table 2|
|sc-12-0823_sm_supplTable3.pdf||90K||Supplementary Table 3|
|sc-12-0823_sm_supplTable4.pdf||81K||Supplementary Table 4|
|sc-12-0823_sm_supplTable5.pdf||84K||Supplementary Table 5|
|sc-12-0823_sm_supplTable6.pdf||88K||Supplementary Table 6|
|sc-12-0823_sm_supplTable7.pdf||85K||Supplementary Table 7|
|sc-12-0823_sm_supplTable8.pdf||85K||Supplementary Table 8|
|sc-12-0823_sm_supplTable9.pdf||85K||Supplementary Table 9|
|sc-12-0823_sm_supplTable10.pdf||85K||Supplementary Table 10|
|sc-12-0823_sm_supplTable11.pdf||85K||Supplementary Table 11|
|sc-12-0823_sm_supplTable12.pdf||90K||Supplementary Table 12|
|sc-12-0823_sm_supplTable13-A.pdf||82K||Supplementary Table 13A|
|sc-12-0823_sm_supplTable13-B.pdf||82K||Supplementary Table 13B|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.